or Try an Advanced Search...

    Technical Analysis for GANX - Gain Therapeutics, Inc.

    Grade Last Price % Change Price Change
    C 2.32 -7.20% -0.18
    GANX closed down 7.2 percent on Friday, November 1, 2024, on 84 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.
    Earnings due: Nov 12
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Down
    Historical GANX trend table...
    Date Alert Name Type % Chg
    200 DMA Resistance Bearish 0.00%
    Fell Below 20 DMA Bearish 0.00%
    Boomer Buy Setup Bullish Swing Setup 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    200 DMA Resistance Bearish -7.20%
    Crossed Above 20 DMA Bullish -7.20%
    1,2,3 Pullback Bullish Bullish Swing Setup -7.20%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -7.20%
    Inside Day Range Contraction -7.20%
    Older End-of-Day Signals for GANX ...

       Recent Intraday Alerts

    Alert Time
    Possible Inside Day about 19 hours ago
    Down 5% about 22 hours ago
    Down 3% about 23 hours ago
    60 Minute Opening Range Breakdown about 23 hours ago
    Down 2 % about 23 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    GANX Chart by TradingView
    Basic chart:

    Profile

    Gain Therapeutics, Inc., a development stage biotechnology company, develops novel therapeutics to treat rare genetic and neurological disorders caused by protein misfolding in Switzerland and Spain. The company through its in-licensed proprietary Site-Directed Enzyme Enhancement Therapy platform, discovers novel allosteric sites on misfolded proteins, identifies proprietary binding sites, and restores protein folding. It has a research collaboration agreement with Sumitomo Dainippon Pharma Co., Ltd. for the research and development of structurally targeted allosteric regulators to restore functional activity of defective lysosomal enzymes in rare genetic and demyelinating diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Life Sciences Allosteric Regulation Sumitomo Group

    Is GANX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 23 Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2
    Oct 15 Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
    Oct 9 Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference
    Oct 7 Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
    Oct 3 Gain Therapeutics to Participate at Upcoming Investor Conferences
    Sep 30 Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers
    Sep 26 Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
    Sep 19 Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024
    Sep 3 Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference
    Aug 30 Gain Therapeutics reports positive data from Phase I Parkinson’s treatment trial
    See more GANX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.33
    52 Week Low 0.89
    Average Volume 417,572
    200-Day Moving Average 2.55
    50-Day Moving Average 1.85
    20-Day Moving Average 2.45
    10-Day Moving Average 2.57
    Average True Range 0.28
    RSI (14) 51.22
    ADX 34.59
    +DI 17.99
    -DI 17.31
    Chandelier Exit (Long, 3 ATRs) 2.35
    Chandelier Exit (Short, 3 ATRs) 2.42
    Upper Bollinger Bands 3.04
    Lower Bollinger Band 1.86
    Percent B (%b) 0.39
    BandWidth 47.89
    MACD Line 0.18
    MACD Signal Line 0.25
    MACD Histogram -0.0677
    Fundamentals Value
    Market Cap 37.58 Million
    Num Shares 16.2 Million
    EPS -1.81
    Price-to-Earnings (P/E) Ratio -1.28
    Price-to-Sales 1400.35
    Price-to-Book 10.70
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.70
    Resistance 3 (R3) 2.73 2.64 2.64
    Resistance 2 (R2) 2.64 2.55 2.63 2.61
    Resistance 1 (R1) 2.48 2.49 2.44 2.45 2.59
    Pivot Point 2.39 2.39 2.37 2.37 2.39
    Support 1 (S1) 2.23 2.29 2.18 2.19 2.05
    Support 2 (S2) 2.14 2.23 2.12 2.03
    Support 3 (S3) 1.98 2.14 2.00
    Support 4 (S4) 1.94